For the quarter ended March 2025, Alignment Healthcare (ALHC) reported revenue of $926.93 million, up 47.5% over the same period last year. EPS came in at -$0.05, compared to -$0.25 in the year-ago quarter.

The reported revenue represents a surprise of +4.21% over the Zacks Consensus Estimate of $889.48 million. With the consensus EPS estimate being -$0.12, the EPS surprise was +58.33%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Alignment Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Medical Benefit Ratio: 88.4% versus the five-analyst average estimate of 89.6%.
• Health Plan Membership - Ending: 217,500 versus 213,332 estimated by four analysts on average.
• Revenues- Other: $8.89 million compared to the $8.05 million average estimate based on five analysts. The reported number represents a change of +26.2% year over year.
• Revenues- Earned premiums: $918.04 million compared to the $881.46 million average estimate based on five analysts. The reported number represents a change of +47.7% year over year.

View all Key Company Metrics for Alignment Healthcare here>>>

Shares of Alignment Healthcare have returned -0.7% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alignment Healthcare, Inc. (ALHC) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research